(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Market: It’s also a unit offering. Size: 1.43 million units (1,428,572 units) at $6.00 to $8.00 to raise $10.0 million. Each unit consists of one share of common stock and two warrants – each to buy one share of stock. Marizyme’s stock last traded on the OTC at $8.00 on a post-split basis on Nov. 15, 2022, the prospectus says. A 1-for-4 reverse stock split was recently completed. Marizyme disclosed the terms for its NASDAQ uplisting in an S-1/A filing dated Nov. 2, 2022; that filing added R.F. Lafferty & Co. as a joint book-runner and disclosed financial statements for the first six months of 2022. Marizyme filed its S-1 on Feb. 14, 2022.)

(Note: Marizyme’s public offering (NASDAQ uplisting) was expected to price on Nov. 23, 2022, before the U.S. stock market’s open, but no pricing information was readily available at that time.)

Marizyme is a multi-technology life science company dedicated to the acceleration, development and commercialization of medical technologies that promote patient health and present potential for rapid revenue growth. (Incorporated in Nevada)

We are focused on developing three medical technology platforms – DuraGraft, MATLOC and Krillase – each of which is clinically tested and backed by a portfolio of patented or patent-pending assets:

• DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, therefore maintaining endothelial function and structure while improving clinical outcomes.
• MATLOC is a point-of-care, lab-on-chip digital screening and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment. Our Krillase protein enzyme provides therapeutics for wound healing, thrombosis and pet health.
• Krillase-based canine dental hygiene products. Krillase, derived from Antarctic krill, shrimp-like crustaceans, is a combination of endo- and exopeptidases that safely and efficiently breaks down organic material. As a “biochemical knife,” Krillase can potentially break down organic matter, such as necrotic tissue, thrombogenic material, and biofilms produced by microorganisms. As such, it may be useful in the mitigation or treatment of multiple disease states in humans. For example, Krillase may promote faster healing, support the grafting of skin for the treatment of chronic wounds and burns, and reduce bacterial biofilms associated with poor oral health in humans and animals.

All require FDA approval.

Note: Revenue and net loss figures are for the 12 months that ended Sept. 30, 2022.